157 related articles for article (PubMed ID: 10912579)
21. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
Motzer RJ; Nanus DM; O'Moore P; Scher HI; Bajorin DF; Reuter V; Tong WP; Iversen J; Louison C; Albino AP
Cancer Res; 1992 Oct; 52(20):5775-9. PubMed ID: 1394202
[TBL] [Abstract][Full Text] [Related]
22. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
23. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
[TBL] [Abstract][Full Text] [Related]
24. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
25. Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Westermann AM; Dubbelman R; Moolenaar WH; Beijnen J; Rodenhuis S
Ann Oncol; 1997 Aug; 8(8):801-2. PubMed ID: 9332690
[No Abstract] [Full Text] [Related]
26. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
[TBL] [Abstract][Full Text] [Related]
28. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
[TBL] [Abstract][Full Text] [Related]
31. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
35. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
37. [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
Hasuike Y; Motoori M; Hattori T; Fujita J; Mishima H; Sawamura T; Nishishou I; Kikkawa N; Sai H; Hosoki T; Mitomo M
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1909-12. PubMed ID: 10560423
[TBL] [Abstract][Full Text] [Related]
38. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
